Because of this, for the first time in May 2015 (subsequently updated in 2019 and in 2020), the Food and Drug Administration (FDA) published a safety announcement of 73 cases of ketoacidosis in T1DM or T2DM patients treated with SGLT2-i drugs from March 2013 (date of the first drug of the class) to May 2015 [37]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.